DBV Technologies S.A. (DBVT)
$9.80+2.62%Close
SELLCRISIS · day 22
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $234M
- Beta
- -0.21
- P/E (TTM)
- -2.55
- Short % float
- 7.73%
- Days to cover
- 3.9
- SI change
- -16.9%
- 1W
- -7.11%
- 1M
- -24.44%
- vs SPY 1W
- -8.27%
- vs SPY 1M
- -27.43%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 3
- GROWTH
- 2
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-71.7%
REV YoY-
ROE-119.5%
EPS YoY-
ROA-79.0%
GROSS-122
OP-3166
NET-3075
[VALUATION]
P/E TTM-2.55
P/E FWD-
SECTOR PE20.47
INDUSTRY PE13.95
P/B5.38
P/FCF-
EV/EBITDA-1.11
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E13.58
ALTMAN Z-
CURR RATIO3.72
ND/EBITDA-
BETA-0.21
Company news
FAQ
- What is LOPJLB’s current signal on DBVT?
- LOPJLB’s latest quantitative signal on DBV Technologies S.A. (DBVT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is DBVT in?
- DBV Technologies S.A. (DBVT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does DBV Technologies S.A. (DBVT) do?
- DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes …